Valsartan

Introduction Overview

Generic Name

valsartan

Brand Name

Diovan

Dosage Form

oral tablet

Drug Class

Angiotensin receptor blockers (ARBs)

Pharmacokinetics

Absorption:
Valsartan is administered orally, primarily as an oral tablet, with good absorption from the gastrointestinal tract. After oral administration, valsartan reaches peak plasma concentrations within 2 to 4 hours, with an absolute bioavailability of approximately 25%. Food intake reduces the bioavailability by about 40%, though this reduction is not considered clinically significant, and thus valsartan can be taken with or without food. The oral absorption process is influenced by gastric pH and motility but is generally consistent across patient populations. The drug exhibits dose-proportional pharmacokinetics within the therapeutic dose range.

Distribution:
Once absorbed, valsartan has a volume of distribution ranging from 17 to 35 liters, indicating moderate distribution primarily into extracellular fluids and tissues. It is highly bound (>95%) to plasma proteins, especially serum albumin, which limits its free circulating fraction. Valsartan does not penetrate the central nervous system significantly due to its physicochemical properties and limited blood-brain barrier permeability. It distributes preferentially to target tissues expressing angiotensin II type 1 (AT1) receptors, such as vascular smooth muscle cells and the adrenal cortex.

Metabolism:
Valsartan undergoes minimal hepatic metabolism, with approximately 20% of the absorbed dose metabolized primarily by the CYP2C9 enzyme pathway, although this metabolic pathway is not the primary route of elimination. The primary metabolite is an inactive acyl glucuronide conjugate, which does not contribute significantly to the pharmacologic activity. The minimal hepatic metabolism limits significant drug interactions related to cytochrome P450 enzymes. First-pass metabolism is limited, contributing to relatively consistent plasma drug levels.

Elimination:
Valsartan is eliminated predominantly unchanged via fecal excretion (~70%), largely through biliary secretion, and to a lesser extent via renal excretion (~30%) of unchanged drug. The elimination half-life ranges between 6 to 9 hours, supporting once or twice daily dosing regimens depending on the indication. Clearance is reduced in patients with severe hepatic impairment and heart failure, necessitating dose adjustments. Renal impairment moderately affects elimination but does not require significant dosage modification in most cases. The pharmacokinetics of valsartan remain stable in elderly patients with appropriate clinical monitoring.

Dosage Forms

Available Dosage Forms:
Valsartan is commercially available primarily as oral tablets with the following strengths: 40 mg, 80 mg, 160 mg, and 320 mg.
For pediatric patients and those who cannot swallow tablets, valsartan is also prepared as an oral suspension by pharmacists, allowing flexible dosing. This suspension is supplied in glass bottles with child-resistant screw-cap closures and may be stored at room temperature (below 30 ºC or 86 ºF) for up to 30 days or refrigerated (2 ºC to 8 ºC) for up to 75 days.

Dosages for Adults and Adolescents:
- Hypertension: Initial adult dose is typically 80 to 160 mg once daily, titratable to a maximum of 320 mg once daily based on response and tolerability.
- Heart Failure: Initiate adults at 40 mg twice daily with dose adjustments up to 160 mg twice daily.
- Post-myocardial infarction (post-MI): Starting dose 20 mg twice daily, titrated to 160 mg twice daily.

Pediatric Use:
- Approved for children 1 year and older for hypertension management.
- Initial pediatric dose is 1 mg/kg once daily (maximum 40 mg/day).
- Dose may be increased up to 4 mg/kg once daily (maximum 160 mg/day).
- Pediatric formulations typically require the compounded oral suspension when appropriate tablet strengths or swallowing ability are limited.

Specific Patient Populations:
- In patients with liver impairment or severe heart failure, lower initial doses and careful titration are recommended to mitigate increased systemic exposure.
- Renal impairment generally does not require dosage adjustment; however, monitoring of renal function is advised during therapy.
- Geriatric patients should be started at the lower end of the dosing spectrum and monitored closely for hypotension or renal function decline.

Mechanism Of Action

Valsartan is a selective angiotensin II receptor blocker (ARB) that exerts its primary pharmacologic action by specifically blocking the binding of angiotensin II to the angiotensin type 1 (AT1) receptor. Angiotensin II is a potent vasoconstrictor and a critical regulator of blood pressure via the renin-angiotensin-aldosterone system (RAAS). By inhibiting the interaction with AT1 receptors located in vascular smooth muscle, adrenal gland, and other tissues, valsartan effectively prevents vasoconstriction and aldosterone secretion.

On a cellular level, antagonism of AT1 receptors leads to vasodilation, reduced aldosterone-mediated sodium and water retention, and decreased sympathetic nervous system activation. This results in lowering peripheral vascular resistance and blood volume, thus reducing blood pressure and cardiac workload. The decreased aldosterone release also impairs cardiac and vascular remodeling processes by reducing fibrosis.

Biochemically, valsartan's blockade of the AT1 receptor inhibits second messenger pathways including phospholipase C activation, inositol triphosphate formation, and intracellular calcium release, which collectively mediate vasoconstriction and tissue proliferation. Importantly, valsartan does not inhibit angiotensin-converting enzyme (ACE) and therefore does not increase bradykinin levels, which reduces the incidence of cough and angioedema commonly seen with ACE inhibitors.

Clinically, valsartan improves outcomes in hypertension, heart failure, and post-myocardial infarction patients by reducing the deleterious effects of excessive angiotensin II stimulation, such as hypertrophy, fibrosis, and progression of cardiovascular and renal disease. Comparative studies show valsartan has similar efficacy to other ARBs and ACE inhibitors, with a favorable side effect profile. Research also supports its role in combination therapy with other antihypertensives for additive effects. Ongoing investigations explore its impact on inflammatory and oxidative stress pathways in cardiovascular pathology.

Pharmacological Actions

Selective antagonism of angiotensin II type 1 (AT1) receptors, blocking vasoconstriction.
Reduction of aldosterone secretion leading to decreased sodium and water retention.
Vasodilation resulting in decreased peripheral vascular resistance and blood pressure.
Inhibition of cardiac and vascular remodeling by reducing fibrosis and hypertrophy.
Minimal impact on bradykinin metabolism, lowering risk of cough and angioedema.
Reduction in sympathetic nervous system activation associated with angiotensin II.
Improvement in left ventricular function and survival post-myocardial infarction.
Modulation of renal hemodynamics, preserving kidney function in chronic conditions.
Lack of significant cytochrome P450 interaction, minimizing drug-drug interactions.
Facilitation of improved fluid balance through decreased renal sodium reabsorption.
Demonstrated anti-hypertensive and anti-heart failure efficacy in clinical trials.
Potential renoprotective effects in diabetic nephropathy and chronic kidney disease.
Reduced hospitalization rates in heart failure patients by improving cardiac output.
Long half-life allows flexible once or twice daily dosing regimens.
Compatibility for use in combination with diuretics and other antihypertensives.

Therapeutic Or Clinical Uses

Treatment of essential hypertension in adults and children aged 1 year and older.
Management of heart failure to reduce hospitalizations and symptoms in adults.
Secondary prevention to increase survival following myocardial infarction with left ventricular dysfunction or heart failure.
Adjunct therapy to lower elevated blood pressure when monotherapy is insufficient.
Used in hypertensive patients with concomitant diabetes or chronic kidney disease for renoprotection.
Alternative therapy to ACE inhibitors in patients intolerant to ACE-induced cough.
Treatment of left ventricular dysfunction and post-MI remodeling.
Combination therapy with diuretics such as hydrochlorothiazide for enhanced antihypertensive effect.
Use in patients at increased cardiovascular risk to reduce morbidity and mortality.
Off-label investigations include potential benefit in diabetic nephropathy progression slowing.
Utilized in clinical practice guidelines for management of hypertension and heart failure.
Appropriate for elderly patients with considerations for titration and monitoring.
Potential use in resistant hypertension in combination with other antihypertensives.
Part of neurohormonal blockade strategies reducing progression of heart failure.
Management of hypertension in patients with metabolic syndrome or obesity.

Side Or Adverse Effects

Headache, commonly occurring especially during early treatment phases.
Dizziness or lightheadedness, frequently related to blood pressure lowering effects.
Fatigue or tiredness reported in some patients undergoing treatment.
Gastrointestinal discomfort, such as abdominal pain or diarrhea.
Flu-like symptoms including malaise or upper respiratory tract symptoms.
Hypotension, particularly in volume-depleted or elderly patients.
Hyperkalemia due to decreased aldosterone secretion and potassium retention.
Elevated blood creatinine or renal impairment, especially in patients with preexisting kidney disease.
Joint and back pain observed in patients treated for heart failure.
Low blood pressure episodes leading to syncope or falls if not monitored.
Cough is less common compared to ACE inhibitors but can rarely occur.
Serious allergic reactions or angioedema, although less frequent than ACE inhibitors.
Potential teratogenicity causing fetal injury or death if used during pregnancy.
Rare hepatic enzyme elevations or hepatitis reported post-marketing.
Electrolyte imbalances including hyponatremia in susceptible individuals.

Precautions

Use with caution in patients with impaired renal function or chronic kidney disease.
Monitor potassium levels closely when used with potassium supplements or potassium-sparing diuretics.
Assess blood pressure regularly to avoid symptomatic hypotension.
Adjust dose carefully in elderly patients to minimize risk of orthostatic hypotension.
Avoid use during pregnancy due to risk of fetal morbidity and mortality.
Evaluate for volume depletion prior to initiation to prevent excessive hypotension.
Exercise caution in patients with bilateral renal artery stenosis or renal impairment.
Use prudently in patients with hepatic impairment as metabolism and clearance may be affected.
Advise patients to avoid salt substitutes containing potassium without consulting healthcare provider.
Instruct patients on maintaining adequate hydration, especially when experiencing vomiting or diarrhea.
Be cautious when combining with other antihypertensives to prevent additive hypotensive effects.
Carefully assess patients with heart failure for worsening renal function during therapy.
Avoid abrupt discontinuation to prevent potential rebound hypertension or heart failure exacerbation.
Evaluate for signs of angioedema or hypersensitivity reactions periodically.
Monitor lithium levels closely if coadministered due to risk of lithium toxicity.

Warnings

Risk of fetal harm and death if used during pregnancy; discontinue immediately if pregnancy detected.
Potential for symptomatic hypotension especially in volume- or salt-depleted patients.
May cause or worsen renal impairment, requiring monitoring of renal function during therapy.
Hyperkalemia risk increased with concomitant potassium supplements or potassium-sparing agents.
Not recommended for use in children under 1 year of age due to insufficient safety data.
Patients undergoing dialysis, or with heart failure, are at higher risk of hypotension.
Avoid use with aliskiren in patients with diabetes or renal impairment due to increased adverse effects.
Serious angioedema, though rare, may occur and requires immediate discontinuation.
Potential for interaction with NSAIDs leading to decreased antihypertensive effect or kidney injury.
Patients should be advised to recognize signs of low blood pressure and seek medical advice.
Use caution in hepatic impairment due to altered drug metabolism and increased exposure.
Excessive sweating, vomiting, or diarrhea requires clinical reassessment to prevent volume depletion.
Concomitant use with lithium requires monitoring due to risk of elevated lithium plasma levels.
Possible carcinogenic impurities in some generic formulations led to recalls and lawsuits; ensure use of trusted manufacturers.
Adjust dosing carefully in elderly and those with comorbid conditions to reduce risk of adverse events.

Contraindication

Known hypersensitivity or allergy to valsartan or any component of the formulation.
Pregnancy due to risk of fetal toxicity and death.
Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment.
Patients with a history of angioedema related to previous ARB therapy.
Severe hepatic impairment or biliary obstruction without appropriate monitoring.
Use in children under 1 year of age due to lack of established safety and efficacy.
Known hypersensitivity reactions to other angiotensin II receptor blockers may warrant avoidance.
Combination with sacubitril (Entresto) requires a washout period; concomitant use is contraindicated.
Severe hypotension or volume depletion states without prior correction.
Concomitant use with potassium-sparing diuretics or potassium supplements without monitoring.
Use of contaminated or recalled batches of valsartan containing nitrosamine impurities.
Significant bilateral renal artery stenosis due to risk of worsening renal function.
Patients with unstable angina or recent cardiac surgery without medical supervision.
Known or suspected pregnancy testing prior to initiation to avoid teratogenic risk.
Any condition where reduction of blood pressure could cause harm, such as critical aortic stenosis.

Drug Interactions

Concomitant use with diuretics (e.g., furosemide, hydrochlorothiazide) can increase the risk of hypotension and renal impairment.
Potassium supplements or potassium-sparing diuretics (e.g., spironolactone) can lead to hyperkalemia when combined with valsartan.
Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce antihypertensive efficacy and increase the risk of renal function deterioration.
Lithium levels may increase when administered with valsartan, posing a risk for lithium toxicity; monitoring is essential.
Combination with ACE inhibitors may increase the risk of hypotension, hyperkalemia, and renal dysfunction.
Aliskiren coadministration is contraindicated in diabetic or renally impaired patients due to increased adverse effects.
Concomitant use with other antihypertensive agents can produce additive hypotensive effects, requiring dose adjustment and monitoring.
Use with CYP450 enzyme inducers or inhibitors is not clinically significant due to limited hepatic metabolism of valsartan.
Interaction with sacubitril requires a 36-hour washout period before starting valsartan to avoid angioedema.
Lithium toxicity risk due to decreased renal clearance when coadministered.
Drugs that impact renal perfusion (e.g., ciclosporin, tacrolimus) may potentiate nephrotoxic effects when combined.
Concomitant use with certain diuretics can cause volume depletion leading to excessive hypotension.
Hyperkalemia risk is increased with simultaneous administration of trimethoprim-containing antibiotics.
Concomitant administration with digoxin is not clinically significant but requires monitoring due to potential pharmacodynamic interactions.
Alcohol intake may potentiate hypotensive effects and should be used cautiously.

Preparations Of The Drug

Valsartan oral tablets: available strengths 40 mg, 80 mg, 160 mg, and 320 mg.
Valsartan oral suspension (compounded): suitable for pediatric patients or those unable to swallow tablets; stored in glass bottles with child-resistant caps.
Combination products include valsartan with sacubitril (Entresto) for heart failure management.
Combination products of valsartan with hydrochlorothiazide (Diovan HCT) for enhanced blood pressure control.
Combination preparations with amlodipine (Exforge) for resistant hypertension.
Triple combination of valsartan, amlodipine, and hydrochlorothiazide (Exforge HCT) for difficult-to-control hypertension.
Combination with nebivolol (Byvalson, discontinued) previously used for hypertension.
Available as branded (Diovan) and multiple generic formulations from several manufacturers.
Packaging designed to protect from moisture; tablets stored at room temperature 20 ºC to 25 ºC.
Oral suspension storage instructions include room temperature (<30 ºC) or refrigeration (2 ºC to 8 ºC), with specified shelf life.
Inactive ingredients in tablets include colloidal silicon dioxide, crospovidone, hydroxypropyl methylcellulose, iron oxides, magnesium stearate, microcrystalline cellulose, polyethylene glycol 8000, and titanium dioxide.
Formulations are designed for once or twice daily dosing according to the indication and patient tolerance.
Packaging includes detailed patient information leaflets addressing dosing, storage, and side effects.
Liquid suspensions must be shaken well prior to administration to ensure proper dosing accuracy.
Controlled distribution by manufacturers adhering to quality standards to prevent contamination and impurities.